FARAMPATOR

also known as Org 24448 · CX 691 · SCH-900460

Developed for: major depressive disorder · schizophrenia
Investigated by: Beth Israel Deaconess Medical Center · Columbia University · Dennis Charney · Duke University · Massachusetts General Hospital · Nathan Kline Institute for Psychiatric Research
+5 more
· National Institute of Mental Health (NIMH) · National Institutes of Health (NIH) · University of California, Los Angeles · University of Maryland · Washington University School of Medicine

20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 2	NCT00425815	Apr 2009	schizophrenia	University of California, Los Angeles	Withdrawn	No outcome recorded
Phase 2	NCT00113022	May 2005 → Feb 2007	major depressive disorder	National Institute of Mental Health (NIMH)	Terminated	Missed primary
Phase 2	NCT00262665	Mar 2005	major depressive disorder	Dennis Charney	Withdrawn	No outcome recorded

Every value below carries the sentence it was read from. 4 sources stand behind the page.

Field	Value	Cited text
Known as	FARAMPATOR	ChEMBL registry synonym — accepted as the source's own label CHEMBL1276138 ↗
Known as	CX 691	ChEMBL registry synonym — accepted as the source's own label CHEMBL1276138 ↗
Known as	Org 24448	ClinicalTrials.gov intervention name — accepted as the source's own label NCT00113022 ↗ 2 NCT00425815 ↗ NCT00262665 ↗
Known as	SCH-900460	ChEMBL registry synonym — accepted as the source's own label CHEMBL1276138 ↗
Modality	Small molecule	— CHEMBL1276138 ↗
Route	Oral	“will be ingested orally daily for eight weeks.” NCT00425815 ↗